Ginkgo BioworksDNA
About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Employees: 834
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
290% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $7.59M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
49% more capital invested
Capital invested by funds: $215M [Q3] → $319M (+$104M) [Q4]
38% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 26
10.79% more ownership
Funds ownership: 61.13% [Q3] → 71.92% (+10.79%) [Q4]
5% more funds holding
Funds holding: 158 [Q3] → 166 (+8) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
Research analyst outlook
We haven’t received any recent analyst ratings for DNA.
Financial journalist opinion
Based on 5 articles about DNA published over the past 30 days
